Drug Profile
Research programme: cancer therapy - Takeda
Alternative Names: cancer therapy research programme - TakedaLatest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Shire BioChem
- Class
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 17 May 2004 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 30 Apr 2002 Preclinical trials in Cancer in Canada (unspecified route)